A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2015-06-23
This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin
(Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants
with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Atorvastatin up
to 20 mg. There is no formal hypothesis for the study.
A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety
CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety
CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
